Replies to post #146825 on Biotech Values

[mojojojo]

Well I am expecting triple failure of all their trials this fall(NSCLC 1st & 2nd line, Pancreatic).

Never said that I expected not to help patients, just not enough to matter(statistically).

So you're saying that all phase 2 trials that aren't powered to return statistically significant results should be considered failures. If that were the case you could probably count the number of drugs that made it to phase 3 on one hand.